Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid LeukemiaJacqueline Cloos *1,2, Jeffrey R. Harris *3, Jeroen J.W.M. Janssen 1, Angele Kelder 1, F. Huang 3, Gerrit Sijm 1, Maike Vonk 1, Alexander N. Snel 1, Jennifer R. Scheick 1, Willemijn J. Scholten 1, Jannemieke Carbaat-Ham 1, Dennis Veldhuizen 1, Diana Hanekamp 1, Yvonne J.M. Oussoren-Brockhoff 1, Gertjan J.L. Kaspers 2,4, Gerrit J. Schuurhuis 1, A. Kate Sasser 3, Gert Ossenkoppele 1
1Department of Hematology, VU University Medical Center, 2Pediatric Oncology/Hematology, VU University Medical Center, 3Janssen Research & Development, LLC, 4Princess Máxima Center for Pediatric Oncology
Detection of minimal or measurable residual disease (MRD) is an important prognostic biomarker for refining risk assessment and predicting relapse in acute myeloid leukemia (AML). These comprehensive guidelines and recommendations with best practices for consistent and accurate identification and detection of MRD, may aid in making effective AML treatment decisions.
